Athira Pharma ATHA 深 滬
等待開盤 12-23 09:30:00 美东时间
7.40
+0.430
+6.17%
華盛通- 最 高7.77
- 今 開6.77
- 成交量 62.14万股
- 最 低 6.53
- 昨 收 6.97
- 總市值 2918.49万
- 52周最高 8.36
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 2.195
- 委 比 -81.50%
- 總股本 394.39万
- 歷史最高 347.90
- 量 比 0.05
- 振 幅 17.79%
- 歷史最低 2.195
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Athira Pharma Stock (ATHA) Up Today?
Athira Pharma stock rallied on Thursday alongside a new license agreement and a...
12-18 20:59
Market-Moving News for December 18th
MU: 13% | Micron shares are trading higher following strong Q1 earnings. ATHA: 89% | Athira Pharma To Acquire Rights For Development And Commercialization Of Lasofoxifene, A Clinical Asset In Potentially
12-18 20:19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
12-18 20:05
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Athira Pharma has entered into an agreement to acquire global rights for lasofoxifene, a Phase 3 clinical asset targeting metastatic breast cancer, particularly ESR1-mutated cases. The company secured $90 million in private placement financing, with potential for up to $146 million more, led by Commodore Capital, Perceptive Advisors, and TCGX. Lasofoxifene's ongoing Phase 3 trial, ELAINE-3, is over 50% enrolled, with data expected mid-2027. Athir...
12-18 12:02
Athira Pharma GAAP EPS of -$1.68
Athira Pharma press release (ATHA): Q3 GAAP EPS of -$1.68. Cash, cash equivalents and investments were $25.2 million as of September 30, 2025, compared to $51.3 million as of December 31, 2024. More o...
11-07 07:02
Athena Gold to Participate in Munich Mining Conference 2025
An update from Athena Gold ( ($TSE:ATHA) ) is now available. Athena Gold Corpor...
09-30 19:46
Athira Pharma Has Been Granted A U.S. Patent "Methods of treating neurodegenerative disease (including dementia, Alzheimer's disease, and Parkinson's disease) with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues". https://t.co/NSHLVnfwcm.
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12421276).pn
09-24 04:00
Athira Pharma To Implement 10-For-1 Reverse Stock Split Following Shareholder Approval At May 2025 Annual Meeting
Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it
09-11 21:03
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
Athira Pharma presented Phase 1 trial results for ATH-1105, a novel small molecule targeting neurodegenerative diseases like ALS, at the ALS Nexus 2025 conference. The trial, involving 80 healthy volunteers, demonstrated favorable safety, tolerability, and CNS penetration, supporting further development of the drug candidate. ATH-1105 aims to modulate the neurotrophic HGF system to restore neuronal health. The company highlighted the potential of...
08-14 11:00
Athira Pharma Q2 EPS $(0.18), Inline
Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 74.29 percent increase over losses of $(0.70) per share from the same period last year.
08-08 04:55
